InvestorsHub Logo
Followers 155
Posts 2654
Boards Moderated 0
Alias Born 01/29/2004

Re: FitzyP33 post# 326793

Saturday, 08/21/2021 9:47:08 PM

Saturday, August 21, 2021 9:47:08 PM

Post# of 465464
The chemistry is un-complicated.

What Anavex organic chemists? I don't see any on staff....


Good point. No, Anavex has no staff, full-time chemists. No need for such. Tweaking small organic molecules like blarcamesine can be done by virtually anyone with an advanced degree in chemistry; even, chemistry grad students.

Way back, years ago, when Missling and company were consolidating Anavex Life Sciences Corp around the molecules they had then, they surely contracted out to some competent chemist (or firm) the task of creating all possible isomers or forms of their molecules; which they could then do preliminary efficacy tests on both lab worms (Caenorhabditis elegans) and mice.

But, look up the actual structure of blarcamesine:
https://en.wikipedia.org/wiki/Blarcamesine

There isn't much there to re-structure. Hanging a methyl group or two somewhere might be possible, but almost surely would negatively impact the new molecule's ability to favorably bind to the sigma-1 receptor molecule. Or, the new molecule would bind so well, be such a powerful ligand, that it would disrupt the protein it attaches to, keeping it from functioning. Reaction-modulating proteins are easily "bent out of shape," thereby making them dysfunctional.

I'm betting that chemists competent in the subject could simply look at blarcamesine's structure and be able to tell what modifications of the molecule would be possible; while at the same tell how those structural re-tweakings would impact the molecular dynamics of the sigma-1 receptor protein.

I don't think Missling and his team at Anavex Life Sciences Corp are much concerned about blarcamesine isomers as commercial competitors.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News